Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HBB | P68871 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 8/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | METAP1 | P53582 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28699476 | 0.83 | KDM4E (0.51) | ALDH1A1HBBHSD17B10ACHEKDM4E | |
| SCHEMBL856747 | 0.81 | ACHE (0.56) | ALDH1A1ACHEKDM4EMEN1MAPT | |
| SCHEMBL6117763 | 0.81 | MAPT (0.49) | ALDH1A1HBBHSD17B10ACHEKDM4E | |
| SCHEMBL29769613 | 0.81 | MAPT (0.49) | ALDH1A1HBBHSD17B10ACHEKDM4E | |
| SCHEMBL3948845 | 0.79 | MAPT (0.56) | ALDH1A1ACHEKDM4EMEN1MAPT | |
| SCHEMBL30702212 | 0.79 | MAPT (0.56) | ALDH1A1ACHEKDM4EMEN1MAPT | |
| SCHEMBL5311960 | 0.77 | KMT2A (0.55) | ACHEKDM4EMEN1MAPTKMT2A | |
| SCHEMBL1000380 | 0.77 | ACHE (0.51) | ALDH1A1HSD17B10ACHEKDM4EMEN1 | |
| SCHEMBL6116289 | 0.77 | METAP1 (0.55) | ACHEKDM4EMEN1MAPTKMT2A | |
| SCHEMBL29476747 | 0.77 | ACHE (0.51) | ALDH1A1HSD17B10ACHEKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10688063-B2 | Treating and/or preventing insulin-resistance related weight gain | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-06-23 | — | — | US | disclosed |
| US-20180028488-A1 | TREATING AND/OR PREVENTING INSULIN-RESISTANCE RELATED WEIGHT GAIN | UNIVERSITY OF SOUTH FLORIDA (US) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028488-A1 | TREATING AND/OR PREVENTING INSULIN-RESISTANCE RELATED WEIGHT GAIN | IGFBP1, IGFBP2, ACACA | ALDH1A1 703/4885HBB 2032/4885HSD17B10 142/4885 |
| US-10688063-B2 | Treating and/or preventing insulin-resistance related weight gain | IGFBP1, IGFBP2, ACACA | ALDH1A1 703/4885HBB 2032/4885HSD17B10 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.